ATAI Life Sciences N.V’s recent filing unveils that its Officer SAHIL KIRPEKAR acquired Company’s shares for reported $0.2 million on Jun 04 ’25. In the deal valued at $2.48 per share,80,000 shares were bought.
Then, Kirpekar Sahil sold 48,563 shares, generating $65,560 in total proceeds. Upon selling the shares at $1.35, the Chief Business Officer now owns 115,636 shares.
Before that, Craig Kevin James sold 11,563 shares. ATAI Life Sciences N.V shares valued at $15,610 were divested by the Chief Medical Officer at a price of $1.35 per share. As a result of the transaction, Craig Kevin James now holds 8,437 shares, worth roughly $20333.170000000002.
H.C. Wainwright reiterated its ATAI Life Sciences N.V [ATAI] rating to a Buy in a research note published on November 18, 2024; the price target was $10. A number of analysts have revised their coverage, including Maxim Group’s analysts, who increased its forecast for the stock in early April from “a Hold” to “a Buy”. Loop Capital began covering ATAI with “Buy” recommendation on November 01, 2022. Maxim Group started covering the stock on November 30, 2021. It rated ATAI as “a Buy”.
Price Performance Review of ATAI
On Friday, ATAI Life Sciences N.V [NASDAQ:ATAI] saw its stock fall -2.82% to $2.41. Over the last five days, the stock has gained 4.33%. ATAI Life Sciences N.V shares have risen nearly 81.20% since the year began. Nevertheless, the stocks have risen 56.49% over the past one year. While a 52-week high of $2.64 was reached on 06/02/25, a 52-week low of $1.03 was recorded on 04/09/25. SMA at 50 days reached $1.64, while 200 days put it at $1.50.
Levels Of Support And Resistance For ATAI Stock
The 24-hour chart illustrates a support level at 2.34, which if violated will result in even more drops to 2.26. On the upside, there is a resistance level at 2.52. A further resistance level may holdings at 2.62. The Relative Strength Index (RSI) on the 14-day chart is 69.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 23.47%. Stochastics %K at 82.34% indicates the stock is a selling.
The most recent change occurred on November 11, 2021 when ROTH Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
